CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05362773
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:38.462231+00:00
Published At: 2026-01-13T00:00:00+00:00
Record Updated At: 2026-01-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Leukemia, Acute Myeloid", "Myelodysplastic Syndromes", "Classical Hodgkin Lymphoma", "Leukemia, B-cell", "Leukemia, Hairy Cell", "Mastocytosis, Aggressive Systemic", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Chronic Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-13"
protocolSection.identificationModule.nctId: "NCT05362773"
protocolSection.identificationModule.officialTitle: "A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.